As of Friday close, Halozyme Therapeutics Inc.’s (NASDAQ:HALO) stock was down -$2.99, moving down -8.29 percent to $33.08. The average number of shares traded per day over the past five days has been 3,521,260 shares. 2 times new highs have been achieved over the past 5 days, with a -$8.55 fall in that time frame. In the last twenty days, the average volume was 1,855,675, while in the previous 50 days, it was 1,475,826.
Since last month, HALO stock retreated -32.76%. Shares of the company fell to $32.93 on 03/17/23, the lowest level in the past month. A 52-week high of $59.46 was reached on 01/03/23 after having rallying from a 52-week low of $35.47. Since the beginning of this year, HALO’s stock price has dropped by -41.86% or -$23.82, and marked a new high 1 time. However, the stock has declined by -44.37% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
HALO stock investors should be aware that Halozyme Therapeutics Inc. (HALO) stock had its last reported insider trading activity 9 days ago on Mar 09. Torley Helen, the PRESIDENT AND CEO of the company, disposed of 10,000 shares for $42.73 on Mar 09. It resulted in a $427,270 divestment by the insider. Torley Helen sold 10,000 shares at an average price of $43.26 on Mar 08. The insider now owns 623,666 shares following the transaction. On Mar 07, PRESIDENT AND CEO Torley Helen sold 10,000 shares at $45.47 apiece. The transaction was valued at $454,690.
Valuation Metrics
Right now, Halozyme Therapeutics Inc. (HALO) has a P/E ratio of about 22.96. The stock’s beta is 1.27. Besides these, the trailing price-to-sales (P/S) ratio of 6.96, the price-to-book (PB) ratio of 26.25, and the price-to-cash flow ratio of 19.54 may also be considered.
Financial Health
In the three months ended September 29, Halozyme Therapeutics Inc.’s quick ratio stood at 4.90, while its current ratio was 5.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 8.79, and the total debt-to-equity ratio was 8.87. On the profitability front, the trailing twelve-month gross margin is 78.90% percent. In the year ended September 29, operating margins totaled 40.10%. Based on annual data, HALO earned $520.81 million in gross profit and brought in $660.12 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.00%. Return on equity (ROE) for the past 12 months was 98.60%.
In Halozyme Therapeutics Inc.’s quarter-end financial report for September 29, it reported total debt of $1.49 billion against cash and short-term investments of $128.6 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. HALO’s revenue rose 30.74% to $208.98 million during the quarter, while net income inched up to $181.5 million. While analysts expected Halozyme Therapeutics Inc. to report $0.51 quarterly earnings, the actual figure was $0.74 per share, beating the consensus estimate by 45.10%. During the quarter, the company generated $83.58 million in EBITDA. The liabilities of Halozyme Therapeutics Inc. were 1.67 billion at the end of its most recent quarter ended September 29, and its total debt was $1.51 billion. The value of shareholders’ equity is $135.37 million.
Technical Picture
This quick technical analysis looks at Halozyme Therapeutics Inc.’s (HALO) price momentum. With a historical volatility rate of 55.93%, the RSI 9-day stood at 10.10% on 17 March.
With respect to its five-day moving average, the current Halozyme Therapeutics Inc. price is down by -20.54% percent or -$8.55. At present, HALO shares trade -32.85% below its 20-day simple moving average and -28.18% percent below its 100-day simple moving average. However, the stock is currently trading approximately -38.63% below its SMA50 and -28.06% below its SMA200.
Stochastic coefficient K was 1.95% and Stochastic coefficient D was 4.82%, while ATR was 2.10. Given the Stochastic reading of 0.95% for the 14-day period, the RSI (14) reading has been calculated as 13.92%. As of today, the MACD Oscillator reading stands at -4.09, while the 14-day reading stands at -6.31.
Analyst Ratings
Halozyme Therapeutics Inc. downgraded its rating on Halozyme Therapeutics Inc. (NASDAQ: HALO) to a Market perform in a note to investors on March 16, 2023. The analysts firm previously had an Outperform rating on the stock.Halozyme Therapeutics Inc. (HALO) has been rated Overweight by analysts. According to 1 brokerage firm, HALO is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Halozyme Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $52.00, the current consensus forecast for the stock is $26.00 – $68.00. Based on these forecasts, analysts predict Halozyme Therapeutics Inc. (HALO) will achieve an average price target of $52.11.